Form D · Biotechnology
OptMed, Inc.
New York, NY · CIK 0001469988
Offering snapshot reported Aug 11, 2015 · SEC filing
- Reported sold
- $200K Offering amount: $500K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 29, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2015 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Mar 17, 2015 | Initial | $200,000 | No comparison | 3 | SEC filing |
| Jun 27, 2014 | Initial | $75,000 | No comparison | 1 | SEC filing |
| Jun 11, 2013 | Initial | $124,000 | No comparison | 4 | SEC filing |
| Aug 22, 2012 | Initial | $257,321 | No comparison | 8 | SEC filing |
| Feb 3, 2012 | Initial | $321,849 | No comparison | 4 | SEC filing |
| Apr 29, 2011 | Amendment | $600,995 | -$5,408,955vs Apr 28, 2011 | 13 | SEC filing |
| Apr 28, 2011 | Initial | $6,009,950 | No comparison | 13 | SEC filing |
| Sep 1, 2009 | Initial | $2,000,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-245519
Source: Form D, filed Aug 11, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Berg | Director |
| Ervin Braun | Director, Executive |
| Alain Klapholz | Director, Executive |
| Martin Knopf | Executive |
| Kevin Mc Kim | Director |
| Sanket Parekh | Director |
| Steven Sands | Director |
| Martin Sands | Director |
| Howard Schrayer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
601 Lexington Avenue, Suite 5100
New York, NY, 10022
New York, NY, 10022